The polycystic ovary syndrome: treatment with insulin sensitizing agents.
Iuorno
M J
MJ
Department of Internal Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298-0111, USA.
Nestler
J E
JE
D002839:Chromans / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000494:pharmacology; D007333:Insulin Resistance; D008687:Metformin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009765:Obesity / Q000150:complications; D010053:Ovary / Q000187:drug effects / Q000378:metabolism; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000188:drug therapy*; D015398:Signal Transduction; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*; D045162:Thiazolidinediones; D000077288:Troglitazone
D002839:Chromans; D007004:Hypoglycemic Agents; D007328:Insulin; D013844:Thiazoles; D045162:Thiazolidinediones; D008687:Metformin; D000077288:Troglitazone